SCHEMBL3496924

SCHEMBL3496924

Cc1ccc(Nc2ncc(F)c(NC3CC(C)(C)N(C)C(C)(C)C3)n2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.57
BCL6 P41182 2/20 0.49
AXL P30530 2/20 0.47
STK17A Q9UEE5 4/20 0.47
STK17B O94768 1/20 0.47
SYK P43405 4/20 0.47
EGFR P00533 4/20 0.44
ERBB2 P04626 2/20 0.44
KDR P35968 2/20 0.44
AURKA O14965 2/20 0.44
BTK Q06187 2/20 0.44
ITK Q08881 2/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
CDC7 O00311 1/20 0.44
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
DCLK1 O15075 1/20 0.44
PDPK1 O15530 1/20 0.44
DAPK3 O43293 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3496315 0.92 PRKCQ (0.56) PRKCQBCL6AXLSTK17ASTK17B
SCHEMBL3495845 0.92 PRKCQ (0.56) PRKCQBCL6AXLSTK17ASTK17B
SCHEMBL3496389 0.89 PRKCQ (0.54) PRKCQBCL6AXLSTK17ASYK
SCHEMBL3495899 0.89 PRKCQ (0.59) PRKCQBCL6AXLSTK17ASYK
SCHEMBL3495571 0.88 PRKCQ (0.57) PRKCQBCL6AXLSTK17ASYK
SCHEMBL1743511 0.88 BRD4 (0.52) PRKCQBCL6AXLSTK17ASYK
SCHEMBL3495051 0.88 BCL6 (0.63) PRKCQBCL6STK17ASTK17BSYK
SCHEMBL3495333 0.88 PRKCQ (0.53) PRKCQBCL6STK17ASTK17BSYK
SCHEMBL3497242 0.87 PRKCQ (0.52) PRKCQBCL6AXLSYKEGFR
SCHEMBL3495097 0.86 PRKCQ (0.50) PRKCQBCL6AXLSTK17ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885BCL6 3211/4885AXL 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.